In this free webinar, Dr. Frank Lynch, Discovery Life Sciences, will discuss why successful drug development studies often begin and end with high quality immunohistochemistry (IHC) biomarker assays. Attendees will gain insights into Discovery's approach to validating target expression using immunohistochemistry (IHC) assays, a critical step toward cancer drug development. Dr. Lynch will explain how sound, strategic decisions around target expression can be made quickly based on reliable IHC biomarker data, from performing translational studies through to prospectively screening patients into clinical studies designed to increase the likelihood of patient response.
TORONTO, Oct. 11, 2022 /PRNewswire-PRWeb/ -- Many clinical trials fail due to inadequately distinguishing between disease phenotypes and underlying drivers of disease early in drug development. This impacts a biomarker target's ability to accurately predict disease, prognosis and therapeutic response. Researchers must adequately understand expression patterns and base decisions made during early development on data derived from high-quality study cohorts that are diverse, comprehensive, highly characterized and representative of the target population.
Oncology drug target validation is more important than ever, particularly given the major investment into biopharma researchers and companies developing so many new types and classes of oncology therapeutics. A critical aspect of target validation includes developing robust assays to accurately reflect expression in the intended to treat populations. This important work needs to be performed as early in the drug development process as possible. Discovery's expert scientists can quickly and rigorously develop novel clinical trial ready immunohistochemistry (IHC) biomarker assays to assess sensitivity, specificity and reproducibility that can then confidently be leveraged throughout the drug development continuum.
In this webinar, the featured speaker, Discovery's Dr. Frank Lynch, will discuss the development and utility of IHC biomarker assays from early strategic planning through to prospective patient screening in CAP/CLIA laboratories, and decisions around the need and approach to a CDx. Dr. Lynch will cover applications of these IHC biomarker assays at various stages of drug development and how the results help facilitate the successful outcome of clinical studies.
Join Dr. Frank Lynch, Executive VP, Global Head of Sales, Scientific Services, Discovery Life Sciences, for this live webinar on Monday, October 24, 2022, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Leveraging Clinical Trial Ready IHC Assays from Target Validation to Prospective Enrollment and CDx Development.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article